The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA
Open accessAbstract
This study reports on the design of mRNA and adjuvant-loaded lipid nanoparticles for therapeutic cancer vaccination. The use of nucleoside-modified mRNA has previously been shown to improve the translational capacity and safety of mRNA-therapeutics, as it prevents the induction of type I interferons (IFNs). However, type I IFNs were identified as the key molecules that trigger the activation of antigen presenting cells, and as such drive T cell immunity. We demonstrate that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist monophosphoryl lipid A (MPLA). As such, we simultaneously allow high antigen expression in vivo while substituting the type I IFN response by a more controllable adjuvant. This strategy shows promise to induce effective antigen-specific T cell immunity and may be useful to enhance the safety of mRNA vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several preclinical studies have indicated that an unmodified mRNA platform induces a more pronounced type-I IFN-polarized innate immune response [11,62]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [62]
In the citing paper
“In comparison, cationic mRNA LNPs composed of a cationic lipid and cholesterol, or DOPE were found to primarily target the lungs, where they transfect tissueresident DCs, macrophages and endothelial cells [142,157,158].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“Comparative studies performed by our research group and others demonstrated that nucleoside-modified mRNA LNPs outperformed unmodified mRNA LNPs in translation capacity, but failed to elicit successful CTL responses due to the drastically reduced production of type I IFNs [119,157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
In the citing paper
“In a proof-of-concept study, we demonstrated that nucleoside-modified mRNA can be co-delivered with the clinically approved TLR agonist MPLA, achieving functional CTL responses like unmodified mRNA, but with strongly reduced type I IFN responses [157].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [157]
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,937
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., den Eynde, B. J. V., van der Bruggen, P., & Boon, T. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3670 · Cited by 1,176
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
In vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature reviews. Immunology · doi:10.1038/nri2173 · Cited by 761
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E., Lion, E., Tendeloo, V. F. V., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 723
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Alveolar Macrophages Are the Primary Interferon-α Producer in Pulmonary Infection with RNA Viruses
Kumagai, Y., Takeuchi, O., Kato, H., Kumar, H., Matsui, K., Morii, E., Aozasa, K., Kawai, T., & Akira, S. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.013 · Cited by 390
Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs
Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608450 · Cited by 337
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
Mature dendritic cells use endocytic receptors to capture and present antigens
Platt, C. D., Jessica, K., Chalouni, C. M., Ebersold, M. W., Bou-Reslan, H., Carano, R. A. D., Mellman, I., & Delamarre, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910609107 · Cited by 290
Diebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Sousa, C. R. E. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 281
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 273
Jewell, C. M., Bustamante-Lopez, S. C., & Irvine, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105200108 · Cited by 245
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
Fries, L. F., Gordon, D. M., Richards, R. L., Egan, J. E., Hollingdale, M. R., Gross, M. S., Silverman, C., & Alving, C. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.358 · Cited by 228
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 213
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Lint, S. V., Goyvaerts, C., Maenhout, S. K., Goethals, L., Disy, A., Benteyn, D., Pen, J. J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210
Self-citationPepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C. G., Türeci, Ö., & Şahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192
Brown, B. D., Sitia, G., Annoni, A., Hauben, E., Sergi, L. S., Zingale, A., Roncarolo, M. G., Guidotti, L. G., & Naldini, L. (2006) · Blood · doi:10.1182/blood-2006-10-049312 · Cited by 187
mRNA-based dendritic cell vaccines
Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Breckpot, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.957684 · Cited by 186
Self-citationWakim, L. M., Smith, J., Caminschi, I., Lahoud, M. H., & Villadangos, J. A. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.133 · Cited by 167
Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking
Braeckmans, K., Buyens, K., Bouquet, W., Vervaet, C., Joye, P., Vos, F. D., Plawinski, L., Doeuvre, L., Anglés‐Cano, E., Sanders, N. N., et al. (2010) · Nano Letters · doi:10.1021/nl103264u · Cited by 157
Immunostimulating capacities of stabilized RNA molecules
Scheel, B., Braedel, S., Probst, J., Carralot, J., Wagner, H., Schild, H., Jung, G., Rammensee, H., & Pascolo, S. (2004) · European Journal of Immunology · doi:10.1002/eji.200324198 · Cited by 138
Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines
Alving, C. R., Rao, M., Steers, N. J., Matyas, G. R., & Mayorov, A. V. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.35 · Cited by 122
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122
The liposome–protein corona in mice and humans and its implications for in vivo delivery
Caracciolo, G., Pozzi, D., Capriotti, A. L., Cavaliere, C., Piovesana, S., Barbera, G. L., Amici, A. R. D., & Laganà, A. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01316f · Cited by 121
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121
Self-citationEffect of “helper lipid” on lipoplex electrostatics
Hirsch‐Lerner, D., Zhang, M., Eliyahu, H., Ferrari, M. E., Wheeler, C. J., & Barenholz, Y. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.04.008 · Cited by 119
Efficient genetic modification of murine dendritic cells by electroporation with mRNA
Meirvenne, S. V., Straetman, L., Heirman, C., Dullaers, M., Greef, C. D., Tendeloo, V. F. V., & Thielemans, K. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700499 · Cited by 118
Simberg, D., Weisman, S., Talmon, Y., Faerman, A., Shoshani, T., & Barenholz, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302232200 · Cited by 118
Nucleic acids and endosomal pattern recognition: how to tell friend from foe?
Brencicova, E., & Diebold, S. S. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00037 · Cited by 118
Toll‐like receptor ligand activation of murine bone marrow‐derived dendritic cells
Dearman, R. J., Cumberbatch, M., Maxwell, G., Basketter, D. A., & Kimber, I. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02922.x · Cited by 114
Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112
Self-citationTemporal and Spatial Resolution of Type I and III Interferon ResponsesIn Vivo
Pulverer, J. E., Rand, U., Lienenklaus, S., Kugel, D., Ziętara, N., Kochs, G., Naumann, R., Weiß, S., Staeheli, P., Häuser, H., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00303-10 · Cited by 112
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 110
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
Self-citationSelmi, A., Vascotto, F., Kautz‐Neu, K., Türeci, Ö., Şahin, U., von Stebut, E., Diken, M., & Kreiter, S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1869-7 · Cited by 90
Harnessing Biomaterials to Engineer the Lymph Node Microenvironment for Immunity or Tolerance
Andorko, J. I., Hess, K. L., & Jewell, C. M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9708-2 · Cited by 84
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
Dewitte, H., Verbeke, R., Breckpot, K., Smedt, S. C. D., & Lentacker, I. (2014) · Nano Today · doi:10.1016/j.nantod.2014.10.001 · Cited by 71
Self-citationMessenger RNA (mRNA) nanoparticle tumour vaccination
Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70
Pyfferoen, L., Brabants, E., Everaert, C., Cabooter, N. D., Heyns, K., Deswarte, K., Vanheerswynghels, M., Prijck, S. D., Wagemans, G., Dullaers, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1253655 · Cited by 60
Neidhart, J. D., Allen, K. O., Barlow, D. L., Carpenter, M., Shaw, D. R., Triozzi, P. L., & Conry, R. M. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.08.021 · Cited by 55
Andries, O., Filette, M. D., Smedt, S. C. D., Demeester, J., Poucke, M. V., Peelman, L. J., & Sanders, N. N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.033 · Cited by 54
The lung vascular filter as a site of immune induction for T cell responses to large embolic antigen
Willart, M. A. M., de Heer, H. J., Hammad, H., Soullié, T., Deswarte, K., Clausen, B. E., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082401 · Cited by 36
Factors affecting DNA binding and stability of association to cationic liposomes
Even‐Chen, S., Cohen, R., & Barenholz, Y. (2012) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2012.03.006 · Cited by 27
Dewitte, H., Verbeke, R., Breckpot, K., Vandenbroucke, R. E., Libert, C., Smedt, S. C. D., & Lentacker, I. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.024 · Cited by 17
Self-citationWhat the cell surface does not see: The gene vector under the protein corona
Motta, S., Rondelli, V., Cantú, L., Favero, E. D., Aureli, M., Pozzi, D., Caracciolo, G., & Brocca, P. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.01.045 · Cited by 13
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 609
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Self-citationTailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Metadata
- Authors
- Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H.
- Affiliations
- Ghent University Hospital (BE)
- Vrije Universiteit Brussel (BE)
- Ghent University (BE)
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 266
- Pages
- 287-300
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2762387202
- Cited by
- 132
- References
- 66
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 20 · 2020: 16 · 2019: 17 · 2018: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- FWO (G016513N, G0B2814N)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- nucleoside-modified mRNA, TLR agonists, monophosphoryl lipid A, lipid nanoparticles, cancer immunotherapy, mRNA vaccines, type I interferon, adjuvants, antigen-presenting cells, T cell immunity
- MeSH terms
- Animals, Cytidine, Dendritic Cells, Female, Immunotherapy, Lipid A, Lipids, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Cancer Vaccines, Toll-Like Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
